Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ADELBA L TORRES-LOPEZ

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1063826543
CMS profile
564234
Location
SAN JUAN, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$4,104.38

174 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,759.49 170
Education $344.89 4

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ADELBA L TORRES-LOPEZ

NPI 1063826543 · CMS profile ID 564234

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SAN JUAN, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063826543?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ADELBA L TORRES-LOPEZ, NPI 1063826543, CMS profile ID 564234. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063826543?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ADELBA L TORRES-LOPEZ, NPI 1063826543, CMS profile ID 564234. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063826543?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ADELBA L TORRES-LOPEZ, NPI 1063826543, CMS profile ID 564234, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1063826543?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

174 matching records · $4,104.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 174 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 174.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $21.7406/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939897967 CMS
Merck Sharp & Dohme LLC $17.4906/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944413995 CMS
ADC Therapeutics America, Inc. $27.1706/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060938641 CMS
Novartis Pharmaceuticals Corporation $24.3806/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894420769 CMS
Seagen Inc. $24.0405/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904124205 CMS
AstraZeneca Pharmaceuticals LP $20.0005/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915850047 CMS
BeiGene USA, Inc. $18.1905/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940788449 CMS
Genentech USA, Inc. $25.0005/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950770413 CMS
Janssen Pharmaceuticals, Inc $18.4205/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886865887 CMS
Astellas Pharma US Inc $18.2905/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940188393 CMS
Janssen Pharmaceuticals, Inc $19.0405/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886865865 CMS
E.R. Squibb & Sons, L.L.C. $18.2205/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932698895 CMS
Genentech USA, Inc. $25.0005/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950774949 CMS
ABBVIE INC. $25.0005/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892541931 CMS
Amgen Inc. $15.6305/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939897973 CMS
Merck Sharp & Dohme LLC $15.8605/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944412347 CMS
Janssen Pharmaceuticals, Inc $24.9505/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886865857 CMS
Novartis Pharmaceuticals Corporation $24.9405/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894420767 CMS
Novartis Pharmaceuticals Corporation $24.9305/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894420763 CMS
Janssen Pharmaceuticals, Inc $21.9505/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886865871 CMS
E.R. Squibb & Sons, L.L.C. $18.1805/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932698887 CMS
Amgen Inc. $20.0005/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939897971 CMS
Incyte Corporation $16.9404/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943076861 CMS
PBG PUERTO RICO LLC $21.9504/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949538903 CMS
Eli Lilly Export S.A. Puerto Rico Branch $84.9604/23/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917831719 CMS
ABBVIE INC. $20.0004/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892541929 CMS
Eli Lilly Export S.A. Puerto Rico Branch $25.0004/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917834609 CMS
Genentech USA, Inc. $21.9504/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950777463 CMS
Janssen Pharmaceuticals, Inc $17.5404/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886865863 CMS
ADC Therapeutics America, Inc. $25.0004/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060938619 CMS
Merck Sharp & Dohme LLC $21.6104/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944405973 CMS
Gilead Sciences, Inc. $25.0004/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929615047 CMS
Novartis Pharmaceuticals Corporation $23.7804/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894420761 CMS
AstraZeneca Pharmaceuticals LP $21.9504/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914664437 CMS
Incyte Corporation $15.9504/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943076863 CMS
EISAI INC. $21.9504/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910871965 CMS
Seagen Inc. $21.9503/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904124195 CMS
Janssen Pharmaceuticals, Inc $16.0503/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886865861 CMS
Genentech USA, Inc. $16.8503/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950790805 CMS
E.R. Squibb & Sons, L.L.C. $17.2603/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932698863 CMS
AstraZeneca Pharmaceuticals LP $16.2503/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914979343 CMS
PFIZER INC. $99.9903/24/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949422937 CMS
Genentech USA, Inc. $21.9503/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950785285 CMS
BeiGene USA, Inc. $18.1903/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940788451 CMS
Novartis Pharmaceuticals Corporation $21.9603/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894420759 CMS
GENZYME CORPORATION $24.0803/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939052091 CMS
Janssen Pharmaceuticals, Inc $18.1903/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886865875 CMS
ADC Therapeutics America, Inc. $22.0003/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060938615 CMS
E.R. Squibb & Sons, L.L.C. $24.9103/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932698861 CMS
Eli Lilly Export S.A. Puerto Rico Branch $20.0003/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917837275 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,831.65 90
PY2020 $821.99 37
PY2021 $1,767.58 62
PY2022 $4,104.38 174
PY2023 $7,698.54 159
PY2024 $26,603.25 212
PY2025 $30,005.83 198

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,278,642.84 139
PY2024 Recipient $1,537.93 9
PY2024 Principal investigator $422,074.10 42
PY2023 Recipient $3,237.20 2
PY2023 Principal investigator $94,851.88 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

139 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $360.00 12/31/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting No dispute reported 06/30/2026 1202404651
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $15,228.00 12/16/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
STUDY TO EVALUATE LONCASTUXIMAB TESIRINE WITH RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (LOTIS 5) No dispute reported 06/30/2026 1250209181
Principal investigator 1 BeOne Medicines Ltd. $750.00 12/09/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190330863
Principal investigator 1 BeOne Medicines Ltd. $719.91 12/08/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190330151
Principal investigator 1 BeOne Medicines Ltd. $1,439.81 12/08/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190330153
Principal investigator 1 ABBVIE INC. $7,718.10 12/04/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404643
Principal investigator 1 ABBVIE INC. $7,567.30 12/04/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202404647
Principal investigator 1 ABBVIE INC. $750.00 12/03/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202404640
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $750.00 12/03/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent No dispute reported 06/30/2026 1236001775
Principal investigator 1 ABBVIE INC. $750.00 11/25/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202404635
Principal investigator 1 Janssen Research & Development, LLC $750.00 11/21/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity No dispute reported 06/30/2026 1175399628
Principal investigator 1 ABBVIE INC. $2,000.00 11/20/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404627
Principal investigator 1 ABBVIE INC. $750.00 11/20/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202404632
Principal investigator 1 Genentech, Inc. $3,500.00 11/18/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
Ph 3 study in patients with Mantle Cell Lymphoma treated with glofitmab vs R chemo or R Len No dispute reported 06/30/2026 1211540394
Principal investigator 1 Genentech, Inc. $750.00 11/18/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
Ph 3 study in patients with Mantle Cell Lymphoma treated with glofitmab vs R chemo or R Len No dispute reported 06/30/2026 1211540398
Principal investigator 1 Genentech, Inc. $750.00 11/18/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
Ph 3 study in patients with Mantle Cell Lymphoma treated with glofitmab vs R chemo or R Len No dispute reported 06/30/2026 1211540402
Principal investigator 1 Genentech, Inc. $750.00 11/18/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
Ph 3 study in patients with Mantle Cell Lymphoma treated with glofitmab vs R chemo or R Len No dispute reported 06/30/2026 1211540406
Principal investigator 1 Genentech, Inc. $750.00 11/18/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
Ph 3 study in patients with Mantle Cell Lymphoma treated with glofitmab vs R chemo or R Len No dispute reported 06/30/2026 1211540411
Principal investigator 1 Janssen Research & Development, LLC $750.00 11/13/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175399617
Principal investigator 1 Janssen Research & Development, LLC $750.00 11/13/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175399662
Principal investigator 1 BeOne Medicines Ltd. $719.91 11/05/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190330175
Principal investigator 1 BeOne Medicines Ltd. $1,439.81 11/05/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190330177
Principal investigator 1 ABBVIE INC. $4,035.20 11/04/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202404609
Principal investigator 1 ABBVIE INC. $7,718.10 11/04/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404612
Principal investigator 1 SANOFI US SERVICES INC. $650.00 11/03/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226120473
Principal investigator 1 SANOFI US SERVICES INC. $650.00 11/03/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226120477
Principal investigator 1 SANOFI US SERVICES INC. $650.00 11/03/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226120482
Principal investigator 1 BeOne Medicines USA, Inc. $4,750.00 10/28/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190332836
Principal investigator 1 BeOne Medicines Ltd. $50,304.00 10/22/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190330441
Principal investigator 1 Genentech, Inc. $28,025.00 10/20/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211540415
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 10/13/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity No dispute reported 06/30/2026 1175399604
Principal investigator 1 Janssen Research & Development, LLC $750.00 10/13/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity No dispute reported 06/30/2026 1175399634
Principal investigator 1 Janssen Research & Development, LLC $750.00 10/13/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity No dispute reported 06/30/2026 1175399642
Principal investigator 1 ABBVIE INC. $750.00 10/09/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202404590
Principal investigator 1 ABBVIE INC. $10,487.10 10/09/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202404595
Principal investigator 1 ABBVIE INC. $750.00 10/09/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202404599
Principal investigator 1 ABBVIE INC. $750.00 10/09/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202404602
Principal investigator 1 ABBVIE INC. $18,722.60 10/09/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404606
Principal investigator 1 Genentech, Inc. $3,500.00 10/09/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211540418
Principal investigator 1 Genentech, Inc. $750.00 10/09/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211540421
Principal investigator 1 Genentech, Inc. $750.00 10/09/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211540426
Principal investigator 1 ABBVIE INC. $750.00 10/07/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202404583
Principal investigator 1 BeOne Medicines USA, Inc. $4,857.00 10/07/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190333857
Principal investigator 1 ABBVIE INC. $750.00 10/02/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404567
Principal investigator 1 ABBVIE INC. $750.00 10/02/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404571
Principal investigator 1 ABBVIE INC. $750.00 10/02/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404575
Principal investigator 1 ABBVIE INC. $750.00 10/02/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404580
Principal investigator 1 BeOne Medicines Ltd. $719.91 09/17/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336904
Principal investigator 1 BeOne Medicines Ltd. $1,439.81 09/17/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336907
Principal investigator 1 ABBVIE INC. $23,667.80 09/03/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404548
Principal investigator 1 BeOne Medicines Ltd. $2,850.00 09/02/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190338189
Principal investigator 1 BeOne Medicines USA, Inc. $7,020.00 08/19/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190333849
Principal investigator 1 ABBVIE INC. $8,944.00 08/05/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202404536
Principal investigator 1 ABBVIE INC. $10,835.50 08/05/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404540
Principal investigator 1 BeOne Medicines Ltd. $50,304.00 07/30/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190330463
Principal investigator 1 BeOne Medicines Ltd. $719.91 07/29/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336949
Principal investigator 1 BeOne Medicines Ltd. $2,850.00 07/22/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190338185
Principal investigator 1 BeOne Medicines USA, Inc. $6,786.00 07/22/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190333853
Principal investigator 1 BeOne Medicines Ltd. $17,250.00 07/15/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190330861
Principal investigator 1 BeOne Medicines USA, Inc. $13,750.00 07/15/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190332833
Principal investigator 1 BeOne Medicines Ltd. $47,160.00 07/09/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190337351
Principal investigator 1 ABBVIE INC. $16,039.40 07/02/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404524
Principal investigator 1 ABBVIE INC. $13,757.90 07/02/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202404529
Principal investigator 1 BeOne Medicines Ltd. $2,818.56 06/30/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190342251
Principal investigator 1 BeOne Medicines Ltd. $14,092.80 06/30/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190342254
Principal investigator 1 BeOne Medicines Ltd. $719.91 06/23/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190342289
Principal investigator 1 BeOne Medicines Ltd. $2,879.62 06/23/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190342292
Principal investigator 1 Janssen Research & Development, LLC $32,500.00 06/23/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175399623
Principal investigator 1 BeOne Medicines USA, Inc. $2,263.00 06/17/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190338832
Principal investigator 1 BeOne Medicines Ltd. $1,439.81 06/16/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190337016
Principal investigator 1 BeOne Medicines Ltd. $939.52 06/16/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190337021
Principal investigator 1 Genmab A/S $3,500.00 06/11/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235921647
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,241.00 06/04/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
a randomised,open label,phase III study of saruparib AZD5305 plus camizestrant compared with physicians choice CDK4 6 inhibitor plus endocrine therapy or plus camizestrant for the first line treatment of patients with BRCA1,BRCA2,or PALB2 mutations and hormone receptor positive, HER2 negative IHC 0,1+,2+ISH non-amplified advanced breast cancer evoPAR breast01 No dispute reported 06/30/2026 1185549651
Principal investigator 1 BeOne Medicines Ltd. $4,697.60 06/04/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190342368
Principal investigator 1 ABBVIE INC. $15,075.00 06/03/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202404513
Principal investigator 1 ABBVIE INC. $3,789.50 06/03/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202404517
Principal investigator 1 ABBVIE INC. $17,299.10 06/03/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404521
Principal investigator 1 BeOne Medicines Ltd. $50,304.00 06/02/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190330427
Principal investigator 1 BeOne Medicines Ltd. $2,850.00 05/30/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190326140
Principal investigator 1 ABBVIE INC. $3,500.00 05/29/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202404505
Principal investigator 1 BeOne Medicines Ltd. $1,439.81 05/28/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336767
Principal investigator 1 BeOne Medicines Ltd. $9,395.20 05/28/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336770
Principal investigator 1 BeOne Medicines Ltd. $47,160.00 05/27/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190337269
Principal investigator 1 Janssen Research & Development, LLC $32,500.00 05/23/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity No dispute reported 06/30/2026 1175399650
Principal investigator 1 ABBVIE INC. $750.00 05/15/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202404486
Principal investigator 1 ABBVIE INC. $750.00 05/15/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404497
Principal investigator 1 ABBVIE INC. $2,000.00 05/15/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202404501
Principal investigator 1 ABBVIE INC. $750.00 05/14/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404473
Principal investigator 1 ABBVIE INC. $750.00 05/14/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202404477
Principal investigator 1 ABBVIE INC. $750.00 05/14/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202404480
Principal investigator 1 BeiGene, Ltd. $2,000.00 05/13/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190325098
Principal investigator 1 BeiGene, Ltd. $33,536.00 05/08/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190325764
Principal investigator 1 Eli Lilly and Company $19,050.00 05/07/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187873689
Principal investigator 1 ABBVIE INC. $19,578.00 05/06/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404465
Principal investigator 1 BeiGene, Ltd. $9,395.20 05/05/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323576
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $5,149.30 05/02/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
STUDY TO EVALUATE LONCASTUXIMAB TESIRINE WITH RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (LOTIS 5) No dispute reported 06/30/2026 1250209293
Principal investigator 1 BeiGene, Ltd. $2,000.00 04/29/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325674
Principal investigator 1 BeiGene, Ltd. $750.00 04/29/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325676
Principal investigator 1 BeiGene, Ltd. $36,371.00 04/22/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322456
Principal investigator 1 BeiGene, Ltd. $1,439.81 04/16/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321940
Principal investigator 1 BeiGene, Ltd. $47,160.00 04/16/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323794
Principal investigator 1 BeiGene, Ltd. $5,637.12 04/14/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321950
Principal investigator 1 BeiGene, Ltd. $14,092.80 04/14/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321952
Principal investigator 1 BeiGene, Ltd. $2,879.62 04/14/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321954
Principal investigator 1 ABBVIE INC. $31,268.90 04/03/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404457
Principal investigator 1 BeiGene, Ltd. $15,720.00 04/02/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321988
Principal investigator 1 BeiGene, Ltd. $4,319.43 04/02/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321990
Principal investigator 1 BeiGene, Ltd. $8,612.72 04/02/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321992
Principal investigator 1 BeiGene, Ltd. $1,879.04 04/02/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321994
Principal investigator 1 BeiGene, Ltd. $4,697.60 04/02/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321996
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,305.35 03/19/2025 Non-covered Recipient Entity
Auxilio Mutuo Cancer Center
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent No dispute reported 06/30/2026 1235998810
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $25,000.00 03/19/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
Phase 3b, Open-label study evaluating the efficacy and safety of luspatercept (BMS-986346/ACE-536) initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions No dispute reported 06/30/2026 1236001773
Principal investigator 1 BeiGene, Ltd. $750.00 03/18/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190320362
Principal investigator 1 ABBVIE INC. $750.00 03/13/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404451
Principal investigator 1 BeiGene, Ltd. $31,440.00 03/10/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322000
Principal investigator 1 BeiGene, Ltd. $4,319.43 03/10/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322002
Principal investigator 1 BeiGene, Ltd. $25,838.16 03/10/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322004
Principal investigator 1 BeiGene, Ltd. $7,516.16 03/10/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322006
Principal investigator 1 BeiGene, Ltd. $14,092.80 03/10/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322008
Principal investigator 1 ABBVIE INC. $40,844.70 03/07/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404447
Principal investigator 1 BeiGene, Ltd. $47,160.00 03/05/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322162
Principal investigator 1 Janssen Research & Development, LLC $750.00 02/21/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity No dispute reported 06/30/2026 1175399611
Principal investigator 1 Janssen Research & Development, LLC $750.00 02/21/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity No dispute reported 06/30/2026 1175399656
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 02/21/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity No dispute reported 06/30/2026 1175399667
Principal investigator 1 Janssen Research & Development, LLC $750.00 02/21/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity No dispute reported 06/30/2026 1175399673
Principal investigator 1 BeiGene USA, Inc. $2,000.00 02/20/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190320364
Principal investigator 1 BeiGene USA, Inc. $750.00 02/20/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190320368
Principal investigator 1 AstraZeneca UK Limited $22,750.00 02/18/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (ACRUE) No dispute reported 06/30/2026 1185549649
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,500.00 02/12/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185549647
Principal investigator 1 BeiGene, Ltd. $750.00 02/11/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325672
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $2,000.00 02/10/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
STUDY TO EVALUATE LONCASTUXIMAB TESIRINE WITH RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (LOTIS 5) No dispute reported 06/30/2026 1250209141
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $750.00 02/10/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
STUDY TO EVALUATE LONCASTUXIMAB TESIRINE WITH RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (LOTIS 5) No dispute reported 06/30/2026 1250209143
Principal investigator 1 ABBVIE INC. $4,869.80 02/06/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202404416
Principal investigator 1 ABBVIE INC. $41,012.40 02/06/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404421
Principal investigator 1 ABBVIE INC. $2,000.00 01/29/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202404413
Principal investigator 1 ABBVIE INC. $750.00 01/28/2025 Covered Recipient Teaching Hospital
AUXILIO MUTUO HOSPITAL
M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202404409
Principal investigator 1 BeiGene, Ltd. $22,167.00 01/28/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322454
Principal investigator 1 BeiGene USA, Inc. $750.00 01/21/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190320366
Principal investigator 1 Celgene Corporation $10,000.00 01/03/2025 Covered Recipient Teaching Hospital
Auxilio Mutuo Hospital
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1222305033